Name: The role of HER2 Gene Mutation in Transitional Cell Carcinoma (en Inglés)
Price: 165.22 PEN
Availability: InStock
Author: Mahdi, Ammar Eesa
ISBN: 9786139430871

portada The role of HER2 Gene Mutation in Transitional Cell Carcinoma (en Inglés)

Formato

Libro Físico

Autor

Ammar Eesa Mahdi

Editorial

Noor Publishing

Idioma

Inglés

N° páginas

152

Encuadernación

Tapa Blanda

Dimensiones

22.9 x 15.2 x 0.9 cm

Peso

0.23 kg.

ISBN13

9786139430871

Categorías

Medicina complementaria

The role of HER2 Gene Mutation in Transitional Cell Carcinoma (en Inglés)

Ammar Eesa Mahdi (Autor) · Noor Publishing · Tapa Blanda

Libro Nuevo

S/ 165,22

S/ 330,45

Ahorras: S/ 165,22

50% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Lunes 05 de Agosto y el Lunes 19 de Agosto.

Lo recibirás en cualquier lugar de Perú entre 2 y 5 días hábiles luego del envío.

Reseña del libro "The role of HER2 Gene Mutation in Transitional Cell Carcinoma (en Inglés)"

The urinary bladder cancer (UBC ) are most common type of cancer of the urinary tract. It is regarded as the second and the fourth most common cancer types for males in Iraq and in the United State of America (USA) respectively and as tenth and eleventh most common cancer types for females in both Iraq and USA respectively. HER2/neu protein is glycoprotein produced by HER2 gene which lies in 17q21 (long arm of chromosome 17). This glycoprotein is normally found in lung, breast, urinary bladder, prostate and stomach, and its cytoplasmic portion has enzymatic function (tyrosine kinase activity). This receptor is responsible for the cell survival, normal cell growing and inhibition of apoptosis. HER2/neu protein overexpression is measured by IHC, but when the result of IHC is equivocal to HER2/neu protein (+ 2), Then, HER2 gene amplification is measured by using an accurate and more practical CISH method Several clinical trials are currently investigating the benefit of HER2-targeted therapy in urothelial bladder cancer. Patients with HER2 amplified UBC could potentially profit from these therapies.